MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - mnc pharma
- SANOFI INDIA - TEVA PHARMA (Israel)
SANOFI INDIA vs TEVA PHARMA (Israel) - Comparison Results
SANOFI INDIA 
Change
Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 SANOFI INDIA  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SANOFI INDIA Dec-18 |
TEVA PHARMA Dec-13 |
SANOFI INDIA/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 6,840 | 2,893 | - | |
| Low | Rs | 4,630 | 2,514 | - | |
| Sales per share (Unadj.) | Rs | 1,203.1 | 1,660.6 | - | |
| Earnings per share (Unadj.) | Rs | 165.3 | 103.7 | - | |
| Cash flow per share (Unadj.) | Rs | 209.9 | 238.0 | - | |
| Dividends per share (Unadj.) | Rs | 84.00 | 90.81 | - | |
| Dividend yield (eoy) | % | 1.5 | 3.4 | 43.6% | |
| Book value per share (Unadj.) | Rs | 963.6 | 1,844.6 | - | |
| Shares outstanding (eoy) | m | 23.03 | 848.00 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.8 | 1.6 | 292.8% | |
| Avg P/E ratio | x | 34.7 | 26.1 | 133.2% | |
| P/CF ratio (eoy) | x | 27.3 | 11.4 | 240.5% | |
| Price / Book Value ratio | x | 6.0 | 1.5 | 406.1% | |
| Dividend payout | % | 50.8 | 87.5 | 58.1% | |
| Avg Mkt Cap | Rs m | 132,078 | 2,292,551 | 5.8% | |
| No. of employees | `000 | 3.3 | 44.9 | 7.3% | |
| Total wages/salary | Rs m | 4,068 | 0 | - | |
| Avg. sales/employee | Rs Th | 8,393.8 | 31,330.9 | 26.8% | |
| Avg. wages/employee | Rs Th | 1,232.4 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,153.0 | 1,957.2 | 58.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 27,708 | 1,408,166 | 2.0% | |
| Other income | Rs m | 897 | 0 | - | |
| Total revenues | Rs m | 28,605 | 1,408,166 | 2.0% | |
| Gross profit | Rs m | 6,235 | 385,627 | 1.6% | |
| Depreciation | Rs m | 1,027 | 113,823 | 0.9% | |
| Interest | Rs m | 7 | 27,659 | 0.0% | |
| Profit before tax | Rs m | 6,098 | 244,145 | 2.5% | |
| Minority Interest | Rs m | 0 | 1,109 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -160,268 | 0.0% | |
| Tax | Rs m | 2,292 | -2,981 | -76.9% | |
| Profit after tax | Rs m | 3,806 | 87,967 | 4.3% | |
| Gross profit margin | % | 22.5 | 27.4 | 82.2% | |
| Effective tax rate | % | 37.6 | -1.2 | -3,078.6% | |
| Net profit margin | % | 13.7 | 6.2 | 219.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 15,922 | 951,070 | 1.7% | |
| Current liabilities | Rs m | 6,235 | 829,414 | 0.8% | |
| Net working cap to sales | % | 35.0 | 8.6 | 404.7% | |
| Current ratio | x | 2.6 | 1.1 | 222.7% | |
| Inventory Days | Days | 64 | 91 | 70.1% | |
| Debtors Days | Days | 21 | 96 | 21.8% | |
| Net fixed assets | Rs m | 7,539 | 459,938 | 1.6% | |
| Share capital | Rs m | 230 | 3,466 | 6.6% | |
| Net worth | Rs m | 22,192 | 1,564,206 | 1.4% | |
| Long term debt | Rs m | 0 | 720,027 | 0.0% | |
| Total assets | Rs m | 29,839 | 3,218,112 | 0.9% | |
| Interest coverage | x | 872.1 | 9.8 | 8,874.9% | |
| Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
| Sales to assets ratio | x | 0.9 | 0.4 | 212.2% | |
| Return on assets | % | 12.8 | 3.6 | 355.7% | |
| Return on equity | % | 17.2 | 5.6 | 305.0% | |
| Return on capital | % | 27.5 | 4.9 | 557.9% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 3,739 | 224,389 | 1.7% | |
| From Investments | Rs m | -731 | -79,510 | 0.9% | |
| From Financial Activity | Rs m | -1,972 | -269,170 | 0.7% | |
| Net Cashflow | Rs m | 1,036 | -124,291 | -0.8% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 69.32 Rs / USD
Compare SANOFI INDIA With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare SANOFI INDIA With: AUROBINDO PHARMA WOCKHARDT SHASUN PHARMA DR. DATSONS LABS DIVIS LABORATORIES
|
| |
Today's Market
Sensex Opens Marginally Higher; Capital Goods & Power Stocks Lead(09:30 am)
Asian share markets slipped on Wednesday and the dollar pulled back from three-month lows after Federal Reserve officials tempered expectations in the markets for aggressive monetary easing.
Related Views On News
SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)
May 8, 2019 | Updated on May 8, 2019For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)
Apr 16, 2019 | Updated on Apr 16, 2019Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.
SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)
Mar 5, 2019 | Updated on Mar 5, 2019For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)
Jun 13, 2019We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?
Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)
Jun 14, 2019Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.
Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)
Jun 21, 2019Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.
This Little-Known Opportunity Promises Both Health and Wealth for Your Grandchildren(Profit Hunter)
Jun 20, 2019The next big opportunity that has the potential to make you both rich and healthy.
My Upcoming Stock Recommendation, Backed by Aberdeen Standard Investments, Scores 9.1/10(The 5 Minute Wrapup)
Jun 19, 2019This month's Smart Money Secrets recommendation is from global super investor - Aberdeen Standard Investments.
More|
| |
SANOFI INDIA SHARE PRICE
Jun 26, 2019 10:05 AM
TRACK SANOFI INDIA
- Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SANOFI INDIA
SANOFI INDIA - FRESENIUS KABI ONCO. COMPARISON
COMPARE SANOFI INDIA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.